Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study

The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

from Entrepreneur: Latest Articles The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors. https://ift.tt/eA8V8J December 01, 2021 at 12:01AMhttps://https://ift.tt/3d39si4